Novel Alzheimer's Trials Evaluate Senolytics, Semaglutide, CRISPR, and More

(MedPage Today) -- In July, we reported that lecanemab (Leqembi) won full FDA approval to treat Alzheimer's disease. In this article, we look beyond anti-amyloid agents like lecanemab to see what other targets are being studied to prevent or treat...
Source: MedPage Today Psychiatry - Category: Psychiatry Source Type: news
More News: Alzheimer's | Psychiatry